22.08.2018 22:05:00
|
Dexcom Acquires TypeZero Technologies
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies, Inc. ("TypeZero”). TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery.
Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery ("AID”) and smart pens. The companies share a consistent vision to improve the lives of people with diabetes through innovation.
"As the first iCGM designated by the FDA, DexCom again has the opportunity to lead the market for integrated systems for diabetes management. TypeZero is a great fit for Dexcom as we look to deliver a growing set of tools to both our insulin delivery partners and our customers,” said Steve Pacelli, Dexcom’s Executive Vice President of Strategy & Corporate Development. "Combined with best-in-class CGM technology, we believe TypeZero’s technology and strong team will accelerate our efforts to further differentiate Dexcom’s portfolio.”
"The TypeZero team is excited for our next chapter as part of Dexcom,” said Chad Rogers, TypeZero’s CEO. "For the last several years, our company has been committed to creating diabetes management products that simplify the life of a person with diabetes. As part of Dexcom, we will continue to embrace the mission to empower people with diabetes through innovation.”
Dexcom currently expects to support the first commercial launch of an AID system using the inControl algorithm in 2019.
The terms of the transaction were not disclosed.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) systems for use by people with diabetes and healthcare providers. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information on the Dexcom CGM, visit www.dexcom.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180822005550/en/
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu DexCom Inc.mehr Nachrichten
26.11.24 |
NASDAQ Composite Index-Wert DexCom-Aktie: So viel hätten Anleger mit einem Investment in DexCom von vor 10 Jahren verdient (finanzen.at) | |
22.11.24 |
NASDAQ-Handel: NASDAQ 100 letztendlich mit Kursplus (finanzen.at) | |
22.11.24 |
Handel in New York: NASDAQ 100-Börsianer greifen am Nachmittag zu (finanzen.at) | |
19.11.24 |
NASDAQ Composite Index-Titel DexCom-Aktie: So viel Gewinn hätte ein Investment in DexCom von vor 5 Jahren eingefahren (finanzen.at) | |
15.11.24 |
Verluste in New York: S&P 500 liegt am Nachmittag im Minus (finanzen.at) | |
15.11.24 |
Schwacher Handel: NASDAQ 100 präsentiert sich leichter (finanzen.at) | |
15.11.24 |
Börse New York in Rot: NASDAQ Composite präsentiert sich schwächer (finanzen.at) | |
15.11.24 |
Börse New York: NASDAQ 100 in der Verlustzone (finanzen.at) |